000008703 001__ 8703
000008703 005__ 20251007025527.0
000008703 024__ $$dUS 27863002 A
000008703 024__ $$aUS 2003/0065003 A1
000008703 037__ $$aPATENT
000008703 041__ $$aEnglish
000008703 245__ $$aUse of methylnaltrexone and related compounds
000008703 260__ $$c2003-04-03
000008703 260__ $$g2002-10-23
000008703 336__ $$aPatent
000008703 520__ $$aA method for preventing or treating opioid induced side effects including changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
000008703 690__ $$aBiological Sciences Division
000008703 691__ $$aAnesthesia and Critical Care
000008703 7011_ $$aFoss, Joseph F.$$uUniversity of Chicago
000008703 7011_ $$aRoizen, Michael F.$$uUniversity of Chicago
000008703 7011_ $$aMoss, Jonathan$$uUniversity of Chicago
000008703 7011_ $$aYuan, Chun-Su$$uUniversity of Chicago
000008703 7011_ $$uUniversity of Chicago$$aDrell, William
000008703 7121_ $$aUniversity of Chicago
000008703 7131_ $$aProgenics Pharmaceuticals Nevada Inc.
000008703 7131_ $$aUniversity of Chicago
000008703 7131_ $$aUR Labs Inc.
000008703 8564_ $$9b2200261-34d0-4dfb-b028-5596d577b70f$$s378751$$uhttps://knowledge.uchicago.edu/record/8703/files/US20030065003.pdf$$ePublic
000008703 909CO $$ooai:uchicago.tind.io:8703$$pGLOBAL_SET
000008703 983__ $$aPatent